There is no hotter technology than CRISPR-Cas9 gene editing tools.
Perhaps it is not surprising then that there is a patent dispute over it, which falls into two camps:
(1) Jennifer Doudna & Emmanuelle Charpentier, and (2) Feng Zhang.
Who deserves the intellectual property for use of CRISPR-Cas9 in human cells?
Take our poll.